Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Common Equity (2016 - 2025)

Historic Common Equity for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $568.4 million.

  • Arrowhead Pharmaceuticals' Common Equity rose 91368.17% to $568.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $568.4 million, marking a year-over-year increase of 91368.17%. This contributed to the annual value of $503.4 million for FY2025, which is 16348.17% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Common Equity is $568.4 million, which was up 91368.17% from $503.4 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Common Equity ranged from a high of $684.2 million in Q1 2025 and a low of $56.1 million during Q4 2024
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Common Equity value was $427.6 million (recorded in 2021), while the average stood at $403.6 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 6771.99% in 2024, then surged by 91368.17% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Common Equity (Quarter) stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then plummeted by 56.17% to $173.7 million in 2023, then plummeted by 67.72% to $56.1 million in 2024, then soared by 913.68% to $568.4 million in 2025.
  • Its last three reported values are $568.4 million in Q4 2025, $503.4 million for Q3 2025, and $522.3 million during Q2 2025.